Back to Results

Nuvalent Inc (NUVL)

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. The company’s pipeline includes zidesamtinib (NVL-520), a ROS1-selective inhibitor being evaluated in the Phase 2 portion of the ARROS-1 Phase 1/2 trial for patients with ROS1-positive non-small cell lung cancer; neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor in the Phase 2 portion of the ALKOVE-1 trial; and NVL-330, a brain-penetrant HER2-selective inhibitor in Phase 1a/1b testing. These programs are designed to address treatment resistance, central nervous system-related adverse events, and brain metastases. Nuvalent was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.


Stock Summary Fair Value Profitability & Growth Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Market Cap Free Float / Shares Outstanding
NASDAQ-NUVL
Not available
Not available
Not available
9.834 B
62.2%
Valuation • Fair Value

Nuvalent Inc (NASDAQ-NUVL) Fair Value by Valuation Model

No usable valuation estimate is currently available for Nuvalent Inc (NASDAQ-NUVL); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Nuvalent Inc (NASDAQ-NUVL). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Nuvalent Inc (NASDAQ-NUVL)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

11.21 M

Forward revenue estimate.

EBITDA

-334.3 M

Current operating profitability reference.

EBITDA Forecast

-508.5 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Nuvalent Inc (NASDAQ-NUVL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Nuvalent Inc (NASDAQ-NUVL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Nuvalent Inc (NASDAQ-NUVL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Nuvalent Inc (NASDAQ-NUVL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Nuvalent Inc (NASDAQ-NUVL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Nuvalent Inc (NASDAQ-NUVL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Nuvalent Inc (NASDAQ-NUVL) Stock FAQ

Data-supported answers about Nuvalent Inc (NASDAQ-NUVL), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs

A reliable fair value estimate is not currently available for Nuvalent Inc (NASDAQ-NUVL). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current market capitalization listed for Nuvalent Inc is 9.834 B.

The ticker symbol for Nuvalent Inc is NASDAQ-NUVL, and the stock is listed on NASDAQ.

Nuvalent Inc (NASDAQ-NUVL) is listed on NASDAQ.

The free float listed for Nuvalent Inc is 62.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 509.5 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 249 B
GILD NASDAQ Gilead Sciences Inc Fair Value Overvalued Market Cap 207.9 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 137.5 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 96.399 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 90.518 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 57.239 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 52.434 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 44.031 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 38.077 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 36.058 B
GMAB NASDAQ Genmab AS Fair Value Fair Market Cap 32.603 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 26.451 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 24.093 B
INCY NASDAQ Incyte Corporation Fair Value Undervalued Market Cap 24.048 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 23.855 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 21.287 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Undervalued Market Cap 20.983 B
EXEL NASDAQ Exelixis Inc Fair Value Fair Market Cap 16.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 16.65 B